Trial record 8 of 257 for:
Open Studies | "Shock"
High Volume Veno-venous Hemofiltration Versus Standard Care for Post-cardiac Surgery Shock (HEROICS)
This study is currently recruiting participants.
Verified October 2012 by Assistance Publique - Hôpitaux de Paris
Sponsor:
Assistance Publique - Hôpitaux de Paris
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT01077349
First received: February 26, 2010
Last updated: October 30, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study seeks to determine if early continuous High Volume Veno-venous Hemofiltration (HVHF) reduces 30-day all cause mortality in post-cardiac surgery patients developing shock requiring high doses catecholamines.
| Condition | Intervention | Phase |
|---|---|---|
|
Shock |
Procedure: high volume hemofiltration Procedure: standard care |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Early Continuous High Volume Veno-venous Hemofiltration vs. Standard Care for Post-cardiac Surgery Shock Requiring High Doses Catecholamines. The HEROICS Study: HEmofiltration to Rescue Severe shOck followIng Cardiac Surgery |
Resource links provided by NLM:
Further study details as provided by Assistance Publique - Hôpitaux de Paris:
Primary Outcome Measures:
- Death from all causes at 30 days after randomisation [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Mortality 60 days following study enrollment [ Time Frame: 60 days ] [ Designated as safety issue: Yes ]
- ICU mortality [ Time Frame: 90 days ] [ Designated as safety issue: Yes ]
- Mortality adjusted on the type of surgery and patient severity at randomization [ Time Frame: 90 days ] [ Designated as safety issue: Yes ]
- Mortality 90 days following study enrollment [ Time Frame: 90 days ] [ Designated as safety issue: Yes ]
- Hospital mortality [ Time Frame: 90 days ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 330 |
| Study Start Date: | December 2009 |
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | January 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: high volume hemofiltration |
Procedure: high volume hemofiltration
(80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery. Hemofiltration will be stopped after 48h if diuresis >1500 ml without diuretics and if IV infusion of catecholamines is less than 0.1 microg/kg/min of epinephrine, 0.2 microg/kg/min of norepinephrine or the sum of epinephrine + nor epinephrine/2 is less than 0.1 microg/kg/min. In other cases, hemodiafiltration (CVVHDF) will be initiated until the above objectives are reached, with equal flow rate of dialysate and reinfusion fluid, the sum of which being <35 ml/kg/h (or a maximum of 3500 ml/h).
Other Name: high volume hemofiltration
|
| Active Comparator: standard care |
Procedure: standard care
extra-renal replacement therapy (CVVHDF mode, total effluent <35 ml/kg/h or a maximum of 3500 ml/h) will be initiated only if the following criteria are met:
Other Name: standard care
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Cardiac surgery with cardiopulmonary bypass
Patient still on high doses catecholamines 3 to 24 hours following cardiac-surgical ICU admission. High doses catecholamines is defined by IV infusion of :
- Epinephrine >0.2 microg/kg/min or
- Norepinephrine >0.4 microg/kg/min or
- Epinephrine + (Norepinephrine /2) >0.2 microg/kg/min
- Cardiac assistance using ECMO/ECLS technique are considered equivalent to high doses catecholamines.
- Informed consent has been obtained from next of kin or when consent cannot be obtained, the intervention is randomized, and written informed consent obtained from the patient as soon as he regains consciousness. This practice is consistent with the French law for clinical research.
Exclusion Criteria:
- Age < 18 years
- Pregnancy
- Chronic hemodialysis prior to heart surgery
- Body weight >120 kg
- Moribund state, defined as SAPS 2 score> 90
- Severe underlying disease with survival expectancy of less than 8 days
- Decision to withhold or withdraw active therapeutics
- PrismaFlex machine unavailable in the unit
- Intravascular access with dialysis catheter impossible -
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01077349
Contacts
| Contact: Alain COMBES, MD phD | +33142163818 | alain.combes@psl.aphp.fr |
Locations
| France | |
| Groupe Hospitalier Pitié-Salpêtrière | Recruiting |
| Paris, France, 75013 | |
| Contact: Alain Combes, MD PhD +33142163818 alain.combes@psl.aphp.fr | |
| Principal Investigator: Alain Combes, MD PhD | |
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
| Principal Investigator: | Alain Combes, MD PhD | Assistance Publique - Hôpitaux de Paris |
More Information
No publications provided
| Responsible Party: | Assistance Publique - Hôpitaux de Paris |
| ClinicalTrials.gov Identifier: | NCT01077349 History of Changes |
| Other Study ID Numbers: | P071223 |
| Study First Received: | February 26, 2010 |
| Last Updated: | October 30, 2012 |
| Health Authority: | France: Ministry of Health |
Keywords provided by Assistance Publique - Hôpitaux de Paris:
|
Cardiac surgery Shock Continuous Veno-Venous Haemofiltration |
Continuous Renal Replacement Therapy Renal Insufficiency Acute |
Additional relevant MeSH terms:
|
Shock Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013